Cardiovascular Events Related to Treated Coronary Arteries in Stable Multivessel CAD

Instituto do Coracao

Status

Completed

Conditions

Coronary Artery Disease

Myocardial Ischemia

Multivessel Coronary Artery Disease

Stable Coronary Artery Disease

Treatments

Other: Optimized Medical Therapy

Procedure: Coronary Artery Bypass Grafting

Procedure: Percutaneous Coronary Intervention

Study type

Observational

Funder types

Other

Identifiers

NCT07362108

SDC 6147 25 158

Details and patient eligibility

About

This retrospective cohort study evaluates cardiovascular events directly related to treated coronary arteries in patients with stable multivessel coronary artery disease. Outcomes in patients undergoing coronary artery bypass grafting or percutaneous coronary intervention will be compared with those receiving optimized medical therapy alone. This study aims to improve understanding of how different treatment strategies impact long-term vessel-related outcomes in patients with stable multivessel coronary artery disease.

Full description

Previous studies evaluating coronary revascularization strategies have relied on broad composite endpoints, which may include events unrelated to the treated vessel. This study focuses on vessel-related outcomes, specifically non-fatal myocardial infarction and cardiac death attributable to the treated coronary artery. Patients were selected from the MASS (Medicine, Angioplasty, or Surgery Study) database at a single tertiary center. By analyzing vessel-specific events, this study aims to provide a more accurate assessment of the long-term impact of different treatment strategies in stable multivessel coronary artery disease.

Enrollment

1,695 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Patients with stable multivessel coronary artery disease, defined as ≥70% stenosis in at least two major epicardial coronary arteries, with documented myocardial ischemia and clinical indication for surgical, percutaneous, or medical treatment.

Exclusion criteria

Patients with limited life expectancy, severe left ventricular dysfunction (ejection fraction <35%), recent acute coronary syndrome, recent revascularization procedures, significant valvular disease, chronic kidney disease (creatinine ≥2.0 mg/dL), active malignancy, or inability to complete long-term follow-up.